FDA Approves First-Ever Gene Therapy for Inherited Hearing Loss — And It Will Be Free

FDA Clears Regeneron’s Otarmeni as First Gene Therapy for Genetic Deafness

The US Food and Drug Administration approved Regeneron’s Otarmeni on Thursday. It marks the first-ever gene therapy approved for inherited hearing loss. The condition affects roughly 50 babies born in the United States each year. Regeneron announced it will provide the drug free of charge to eligible US patients.

Otarmeni carries the generic name lunsotogene parvec. It treats a rare form of deafness caused by mutations in a gene called OTOF. This gene normally instructs the body to produce a protein called otoferlin. Without otoferlin, sound signals never reach the brain.

The FDA granted the approval under the Commissioner’s National Priority Voucher (CNPV) pilot program. This program allows the agency to fast-track reviews of products addressing major national interests. The Trump administration designated those priorities. It also represents Regeneron’s first approved genetic medicine.

Regeneron originally acquired this therapy through its 2023 purchase of Decibel Therapeutics. Decibel Therapeutics originally developed the gene therapy. Regeneron has since advanced it through clinical trials. The company now plans to seek regulatory approval in other countries as well.

How the Gene Therapy Works

The OTOF gene plays a critical role in hearing function. It gives the body instructions to make otoferlin. This protein helps transmit pulses from cochlear cells in the ear to nearby nerves. Those nerves carry sound signals onward to the brain.

Otarmeni delivers a working copy of the OTOF gene directly into the body. It uses an adeno-associated virus vector for this delivery. Doctors administer it through an intracochlear infusion. The procedure takes place while the patient is under general anesthesia.

The therapy works continuously once delivered. Dr. Eliot Shearer, a pediatric otolaryngologist at Boston Children’s Hospital, described the key advantage. “The improved hearing is on 24/7 and doesn’t rely on batteries,” he said. Shearer served as a principal investigator on the Regeneron trial.

Previously, cochlear implants were the only treatment option for children with this form of deafness. Implants restore the ability to hear speech and music. However, they reduce the natural fidelity of sound. Gene therapy aims to restore hearing far more naturally.

Strong Results From the CHORD Clinical Trial

The FDA based its approval on results from the Phase I/II CHORD clinical trial. The open-label trial enrolled 20 patients diagnosed with the OTOF mutation. Each patient received a single dose of the therapy in one or both ears. Results showed remarkable improvements across most participants.

Sixteen of the 20 patients met the primary endpoint. They achieved hearing improvement below the severe hearing loss threshold. Doctors measured this through pure tone audiometry at 24 weeks. A seventeenth patient reached the same benchmark by week 48.

Five of 12 patients followed for at least 48 weeks achieved essentially normal hearing levels. These results drew emotional responses from families involved in the trial. Kerri, the mother of a trial participant, described her son’s transformation. “You go from being told your child’s profoundly deaf to your child hearing right alongside his friends,” she said.

Her two-year-old son, Miles, received the gene therapy in both ears in May. Kerri asked that the family’s last name remain private. She called the results “miraculous.” Miles now hears at a level comparable to his peers.

Side Effects and Accelerated Approval Conditions

The trial also identified several adverse reactions linked to the therapy. The most common side effects included middle ear infection and inflammation. Patients also reported vomiting, nausea, and dizziness. Other reactions included procedural pain, gait disturbance, and nystagmus.

The FDA granted Otarmeni accelerated approval status. This means continued approval depends on confirming long-term clinical benefits. Regeneron must complete a confirmatory trial phase. The company expects to verify those benefits within the ongoing CHORD trial’s confirmatory portion.

Accelerated approval pathways allow promising treatments to reach patients faster. The FDA requires companies to follow up with robust clinical data. If Regeneron confirms the therapy’s benefits, full approval will follow. The agency set clear expectations for this confirmation process.

Free Access and Drug Pricing Announcement

Regeneron confirmed it will offer Otarmeni at no cost to eligible US patients. This decision forms part of a broader Most Favored Nation drug pricing deal. Regeneron struck this deal with the Trump administration. The announcement came Thursday alongside the drug’s approval.

The Trump administration revealed similar deals with 17 large pharmaceutical companies. These deals aim to align US drug prices with lower prices in Europe and Asia. Regeneron’s co-founder and president, Dr. George Yancopoulos, explained the company’s thinking. “We want to deliver a gift to people — in this case, the gift of hearing,” he told CNN.

Yancopoulos and Regeneron’s chief executive, Dr. Len Schleifer, appeared at the White House on Thursday. Their appearance coincided with the broader drug pricing announcement. President Donald Trump touted the Otarmeni approval during an Oval Office event. He highlighted it as part of the TrumpRx self-pay platform deal.

However, Regeneron noted one important limitation. The company controls the drug’s list price, not the cost of administering it. Administration requires a surgical procedure similar to cochlear implant surgery. Families should expect separate costs for the medical procedure itself.

Global Access and Future Implications

Otarmeni currently holds approval only in the United States. Regeneron plans to file for regulatory approval in other countries. The company has not yet confirmed whether international patients will receive the drug for free. Gene therapies for rare diseases often carry price tags in the millions globally.

The therapy’s approval signals a major milestone for genetic medicine. It opens a new path for treating congenital hearing loss. Researchers and clinicians hope it will inspire further gene therapy development. Dr. Shearer called the approval “life-changing for families with children with hearing loss.”

The OTOF mutation affects a very small population each year. Yet the impact of treatment on individual lives proves enormous. Miles and the other trial participants now experience a world of sound. Their stories illustrate what targeted genetic medicine can achieve.